自改革开放以来，住房、教育和医药事业的发展一直都是社会各界重点关注的民生问题，其中医药产业作为国民经济发展的重要支柱性产业，有着广阔的发展前景。近年来，为促进医药产业的提质增效，我国针对医药行业的发展制定了相关的政策，鼓励医药企业进行变革，加大研发创新力度，推进产业结构调整，促进医药行业转型升级。虽然，目前我国医药企业发展受到政策利好，但也对医药企业提出了严格的要求，为药企带来更好的发展机会，同时也促使医药行业的市场竞争愈演愈烈。基于医药行业投入成本高和研发周期长的特点，相应的财务风险问题也受到更多的关注。

H公司是一家集研发、生产和销售于一体的医药生物科技公司，论文基于之前学者对财务风险研究的理论基础，选择H公司作为研究对象，识别其可能存在的财务风险，并建立财务风险评价模型，对存在的财务风险提出针对性的防范建议。在财务风险的识别环节，首先对H公司2016-2020年的财务状况做简单分析，然后结合内外部的影响因素对H公司财务风险的成因进行研究，最后从筹资、投资、营运、发展和研发创新五个方面精准识别H公司的财务风险。在财务风险评价方面，基于识别出的H公司的财务风险加以评价，主要从财务风险的五个角度最终确定9个财务指标建立风险评价模型，选择更具有客观性的熵权法确定财务指标的权重，最后采用改进的功效系数法对H公司近五年的指标权重进行计算和评估，并对评估结果做综合分析。分析结果表明：H公司在发展方面处于重大风险状态，投资和营运方面处于高风险状态，筹资和研发创新方面处于低风险状态。论文最后针对H公司存在的筹资风险、投资风险、营运风险、发展风险和研发创新风险提出对应的控制措施，具体为：完善资本结构，降低投资风险，加强存货与应收账款管理，提升盈利能力，增强研发创新质量。因此，文章研究H公司财务风险识别和控制具有一定的理论价值和现实意义，在其他企业进行财务风险的识别及控制时，可以为其提供借鉴和参考。

Since the reform and opening up, the development of housing, education and medicine has always been a key livelihood issue for all sectors of society, among which the pharmaceutical industry, as an important pillar industry in the development of national economy, has broad prospects for development. In recent years, in order to promote the quality and efficiency of the pharmaceutical industry, China has formulated relevant policies for the development of the pharmaceutical industry, encourage pharmaceutical enterprises to carry out reform, increase research and innovation, promote the adjustment of industrial structure, and promote the transformation and upgrading of the pharmaceutical industry. Although the development of China's pharmaceutical enterprises is favorable policies, but also put forward strict requirements for pharmaceutical enterprises, to bring better development opportunities for pharmaceutical enterprises, but also promote the market competition in the pharmaceutical industry more and more fierce. Based on the characteristics of high investment cost and long research and development cycle in the pharmaceutical industry, the corresponding financial risks have also attracted more attention.

H company is a set of research and development, production and sales of pharmaceutical biotechnology company, the paper based on the theoretical basis of financial risk research, choose H company as the research object, identify its possible financial risk, and establish financial risk evaluation model, the financial risk targeted prevention recommendations. In the identification link of financial risk, first make a simple analysis of the financial situation of H Company in 2016-2020, and then study the causes of the financial risk of H Company combined with internal and external influencing factors. Finally, the financial risk of H Company is accurately identified from five aspects: financing, investment, operation, development and research and innovation. In terms of financial risk assessment, based on the identified H company financial risk evaluation, mainly from the five perspectives of financial risk finally determine nine financial indicators risk assessment model, choose more objective entropy method to determine the weight of financial indicators, finally using the improved efficacy coefficient method of the past five years, and make a comprehensive analysis of the evaluation results. The analysis results show that H company is in a significant risk state in development, high risk in investment and operation, and low risk in financing and R & D and innovation. At the end of the paper, the corresponding control measures are proposed for the financing risk, investment risk, operation risk, development risk and R & D and innovation risk of H Company, specifically: improve the capital structure, reduce the investment risk, strengthen the management of inventory and accounts receivable, improve the profitability, and enhance the quality of R & D and innovation. Therefore, this article has certain theoretical value and practical significance to study the financial risk identification and control of H company, which can provide reference and reference in the identification and control of financial risk of other enterprises.

[1]Fitzpatrick PJ. A comparison of the ratios of successful industrial enterprises with those of failed companies [J]. Certified Public Account, 1932(2): 598-605.

[2]Beaver William. Financial ratios as predictors of failure [J]. Journal of Accounting Research, 1966, 4:71-111.

[3]P. A. Tinsley. Capital structure, precautionary balances, and valuation of the firm: the problem of financial risk[J]. Journal of Financial and Quantitative Analysis, 1970, 5(1): 33-62.

[4]S. G. Anton. Who manages financial risk? An empirical examination of risk management practices in the romanian metallurgical industry[J]. Metalurgija, 2013, 52(4): 518-520.

[5]Terry McNulty, Chris Florackis, Phillip Ormrod. Boards of directors and financial risk during the credit crisis[J]. Corporate Governance: An International Review, 2013, 21(1): 58-78.

[6]Martín Ezequiel Masci, María Teresa Casparri, Javier Ignacio García-Fronti. Expert's opinion impact on financial risk management[J]. Int. J. of Business Continuity and Risk Management, 2018, 8(3): 249-261.

[7]Alexandre Trindade, Yun Zhu. Approximating the distributions of estimators of financial risk under an asymmetric Laplace law [J]. Computational Statistics and Data Analysis, 2006, 51(7): 3433-3447.

[8]Elizabeth Sheedy. Agency Risk: The forgotten element in financial risk management[J]. Economic Papers: A journal of applied economics and policy, 1999, 18(4): 80-91.

[9]Prevost A. K., Rose L. C., Miller G. Derivatives usage and financial risk management in large and small economies: a comparative analysis[J]. Journal of Business Finance & Accounting, 2000, 27(5-6): 733-759.

[10]Daniel Agyapong. Analyzing financial risks in small and medium enterprises: evidence from the food processing firms in selected cities in Ghana[J]. International Journal of Entrepreneurial Behavior & Research, 2020, 27(1): 45-77.

[11]Cui X. H., He Z. Q. Application of the fuzzy AHP model based on a new scale method in the financial risk assessment of the listing corporation[J]. Chemical Engineering Transactions (CET Journal), 2015, 46:1231-1236.

[12]Jeehan Almamy, John Aston, Leonard N Ngwa. An evaluation of Altman's Z-score using cash flow ratio to predict corporate failure amid the recent financial crisis: Evidence from the UK [J]. Journal of Corporate Finance, 2016, 36:278-285.

[13]Wei Ran, Yao Sheng. Enterprise financial risk identification and information security management and control in big data environment [J]. Mobile Information Systems, 2021, 2021: 1-6.

[14]Shizhe Zhang. Research on financial risk evaluation of BG shares [J]. Scientific Journal of Economics and Management Research, 2021, 3(4): 142-146.

[15]L. H. Reeves and R. J. Lilieholm. Reducing financial risk in agroforestry planning: a case study in Costa Rica [J]. Agroforestry Systems, 1993, 21(2): 169-175.

[16]Daniel A. Ames, Christopher S. Hines, Jomo Sankara. Board risk committees: insurer financial strength ratings and performance [J]. Journal of Accounting and Public Policy, 2018, 37(2): 130-145.

[17]Rastin Matin et al. Predicting distresses using deep learning of text segments in annual reports[J]. Expert Systems with Applications, 2019, 132: 199-208.

[18]Ibrahim Mallam Fali, Terzungwe Nyor, Lateef Olumide Mustapha. Financial risk and financial performance of listed insurance companies in Nigeria[J]. European Journal of Business and Management, 2020, 12(12): 143-153.

[19]Binder Andreas, Jadhav Onkar, Mehrmann Volker. Model order reduction for the simulation of parametric interest rate models in financial risk analysis[J]. Journal of Mathematics in Industry, 2021, 11(1): 1-34.

[20]张树宏. 中外合资经营企业的风险分析[J]. 外国经济与管理, 1986, 8(02): 4-5.

[21]刘恩禄, 汤谷良. 论财务风险管理[J]. 北京商学院学报, 1989, 9(01): 50-54.

[22]刘柏, 琚涛. 资产金融化、研发创新与财务风险：“共振”抑或“冲销”[J]. 财经科学, 2019, 63(10): 20-29.

[23]陈志斌, 曹佳敏, 王诗雨. 论企业财务风险的产业效应[J]. 财会月刊, 2019, 40(18): 3-9+178.

[24]徐炜, 肖智. 内部控制对企业财务风险影响的非线性特征——理论推演与实证检验[J]. 现代财经(天津财经大学学报), 2019, 39(03): 68-82.

[25]刘鲁晋, 李梦妍. 内部控制视角下食品行业财务风险管理[J]. 合作经济与科技, 2020, 36(24): 130-131.

[26]禹华意. 互联网时代企业财务风险分析与防控[J]. 商场现代化, 2021, 50(03): 184-186.

[27]吴世农, 黄世忠. 企业破产的分析指标和预测模型[J]. 中国经济问题, 1987, 29(06): 8-15.

[28]刘华英, 刘晓英. 议企业财务风险的识别与防范[J]. 中国地质矿产经济, 2002, 20(08): 37-41.

[29]姜昭羽, 于善波. 浅析企业财务风险的识别与内部控制对策[J]. 中国管理信息化, 2019, 22(14): 43-44.

[30]芦笛, 王冠华. 农业上市公司的财务风险预警研究——基于因子分析法和聚类分析法[J]. 会计之友, 2019,37(24): 79-83.

[31]刘照德, 詹秋泉, 田国梁. 因子分析综合评价研究综述[J]. 统计与决策, 2019, 35(19): 68-73.

[32]曹鑫, 阮娴静. 基于因子分析法的我国医药企业创新发展能力评价研究[J]. 中国药房, 2020, 31(16): 1931-1937.

[33]杨柏辰, 张怡, 郭炜. 基于Logistic回归模型的企业财务风险诊断研究[J]. 系统科学学报, 2021, 29(03): 84-87.

[34]张晓晴, 齐延艳. 汽车行业上市公司财务风险预警——基于主成分分析和Logistic回归的财务风险预警模型[J]. 中国集体经济, 2020, 36(27): 92-94.

[35]熊毅, 张友棠. 基于F计分值的上市公司财务风险预警研究[J]. 管理现代化, 2019, 39(01): 111-115.

[36]高翔, 聂赟彬, 李秉龙. 涉农企业金融化与企业财务风险水平研究——基于中国A股上市公司的实证分析[J]. 农业经济与管理, 2019, 10(05): 46-55.

[37]潘雅琼, 刘艳. 科技型企业财务危机预警研究——基于生存分析法[J]. 会计之友, 2021, 39(08): 64-70.

[38]陈标金, 植嘉娟, 区嘉湄. 财政补助、研发投入与企业财务风险——基于A股上市公司的证据[J]. 科技管理研究, 2021, 41(08): 117-123.

[39]赵腾, 杨世忠. 熵权TOPSIS法在企业财务风险评价中的应用——以酒鬼酒公司为例[J]. 财会月刊, 2019, 40(03): 9-16.

[40]王力召, 蒋致远. 基于结构熵权法的P2P平台财务风险评价研究[J]. 系统科学学报, 2020, 28(02): 95-99+128.

[41]桑雨萌, 韩秀平. 基于熵权法的物流金融风险评价模型构建[J]. 商业经济研究, 2019, 38(09): 165-167.

[42]周忆, 张友棠. 基于卡尔曼滤波的僵尸企业财务风险动态预警研究[J]. 财会通讯, 2019, 40(23): 110-114.

[43]侯旭华. 基于模糊综合评价法的互联网保险公司财务风险预警研究[J]. 湖南社会科学, 2019, 32(04): 88-99.

[44]向德伟. 企业财务风险控制初探[J]. 财会月刊, 1995, 16(06): 10-11.

[45]黄伟. 财务管理过程中的风险控制[J]. 山东财政学院学报, 2000, 12(04): 81-85.

[46]王阳, 高翠莲. 企业财务风险控制新思维[J]. 会计之友, 2013, 31(11): 68-70.

[47]韦培勇. 新经济环境下企业集团财务风险及防范措施分析[J]. 现代商贸工业, 2021, 42(16): 81-82.

[48]黄敏. 互联网企业财务风险控制研究[J]. 财会通讯, 2018, 39(14): 109-112.

[49]王峥. 中小企业财务风险控制研究[J]. 营销界, 2019, 22(51): 52-53.

[50]张蓓蓓, 李光龙. 中小型饲料加工企业财务风险控制研究[J]. 中国饲料, 2021, 32(24): 99-102.

[51]梁娟. G公司的财务杠杆效应及财务风险控制分析[J]. 时代金融, 2019, 40(03): 52-54.

[52]肖倩. 高新技术企业财务风险防范与控制策略研究[J]. 现代经济信息, 2019, 34(13): 299.

[53]马晖. 浅谈制药公司财务风险分析与控制[J]. 现代商业, 2019, 14(23): 187-188.

[54]姜文龙. “两票制”背景下YTS医药公司财务风险分析[D]. 郑州大学. 2020.

[55]李波. 上市公司财务风险控制存在的问题及完善对策[J]. 财务与会计, 2021, 43(22): 64-65.